GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (OTCPK:IUGNF) » Definitions » Price-to-Funds-From-Operations

IUGNF (Imugene) Price-to-Funds-From-Operations : (As of Dec. 12, 2024)


View and export this data going back to . Start your Free Trial

What is Imugene Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Imugene Business Description

Industry
Traded in Other Exchanges
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.